You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Personalized Neural Stem Cell Therapy for Cancer
SBC: Falcon Therapeutics, Inc. Topic: NCATSPROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides
SBC: GLYCAN THERAPEUTICS CORPORATION Topic: 300This fast-track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological research. Glycan Therapeutics is a biotech company specialized in synthesizing sulfated carbohydrates using innovative enzyme-based methods. This proposal is focused on the synthesis of large authentic oligosaccharides in the size range of 10-mers to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia
SBC: Arrevus, Inc. Topic: NIAIDBloodstream infections (BSIs) caused by Gram-negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic-resistant nature of the pathogens. Infections caused by multi-drug resistant (MDR) bacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic options. This lack of treatment options is particularly ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Non-Invasive Physiologic Evaluation of Peripheral Arterial Disease
SBC: RFPi, Inc. Topic: NHLBIABSTRACT Peripheral Arterial Disease (PAD) is a substantial healthcare burden in the US (estimated andgt; 8M) and around the world (estimated andgt; 200M). In the aging population, over 24% with age andgt; 80 years have PAD. 50% of all patients with PAD are asymptomatic, and up to 40% of the remaining patients have atypical symptoms. The conventional ankle/brachial index (cABI) ratio is establishe ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Smart Sensing Drill to Reduce Incidence of Dental Implant Complications
SBC: RYTEK MEDICAL INC Topic: NIDCRClinical Importance: Almost 10 million dental implants were placed worldwide in 2016, with 3 million of these procedures taking place in the United States. The worldwide market for these implants is expected to increase to $4.0-$5.0 billion in revenue by 2018 as more patients opt for this procedure to regain chewing function and improve cosmetic appearance. The procedure itself requires an osteoto ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Ultrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker
SBC: Microelastic Ultrasound Systems, Inc. Topic: NCIUltrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker 1 ABSTRACT Sclerotic chronic graft versus host disease (cGVHD) develops in 30 - 70% of allogenic Human Stem Cell Transplant (HCT) recipients and is associated with significant morbidity and mortality. GVHD is treated with immunosuppression, which puts patients at severe risk of infection. I ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast
SBC: CELDARA MEDICAL, LLC Topic: 500Project Summary This project describes the formation, launch and operation of the DRIVEN Accelerator Hub, with the express goal of reducing morbidity and mortality by increasing the number of medical entrepreneurs and their level of competency. The Hub is focused on the Northeast and, in collaboration with similar Hubs, will contribute nationwide. It will, in a facile, complete, and accessible way ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
New Class of Bright Sharp Tunable Near Infrared Fluorophores for Flow Cytometry
SBC: Nirvana Sciences, Inc. Topic: RDESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells Dyes used for FC typically exhibit broad fluorescent emission bands with full width at half maximum fwhm values of nm This limits the maximum numbe ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
The CellRaft AIR System Workflow Automation for Stem Cell Isolation and Recovery
SBC: CELL MICROSYSTEMS INC Topic: 200DESCRIPTION provided by applicant Stem cell research is an emerging field with the promise of creating dramatic new approaches for disease treatment and drug discovery The research and regenerative medicine market space for stem cells is one of the most dynamic areas in the life science industry today Globally the stem cell market is growing at a CAGR of and will reach an approximate ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimer s therapy
SBC: sGC Pharma Inc. Topic: NIADESCRIPTION provided by applicant Alzheimerandapos s disease AD occurs in one out of eight Americans of age and affects of the elderly over Current FDA approved drugs provide short term symptomatic relief of AD There is a pressing need to discover new disease modifying medications AD is multifactorial in origin and progression A drug attenuating several underlying factors is a p ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health